Based in Boston, Massachusetts, Glytec, LLC, is the leading provider of AI-powered technology for diabetes and related conditions, including the Glytec Glucommander. Glytec, LLC serves hospitals and health care systems, and its Glucommander platform provides clinical decision support, workflow alerts, patient monitoring, at-risk patient identification, and AI-driven analytics.
Glytec, LLC, provides leading SaaS technology to more than 400 hospitals, empowering health care professionals with the capability to leverage collaborative diabetes management and insulin dosing through its Glucommander product. This technology has enabled health care providers to improve patient outcomes, reduce readmissions, and streamline their work, thereby enhancing efficiency and promoting health equity. The first-ever FDA-approved product of its type, the Glucommander operates on cloud-based insulin management software that can be integrated into electronic medical records.
The company was named a 2025 Stevie Winner for Technology Excellence Company of the Year and was featured in Healthcare Tech Outlook’s 2025 Top Diabetes Management Platforms. It was also called “The Best Computerized Decision Support Solution” by the MedTech Breakthrough Award Program. Becker’s Healthcare placed the firm’s chief medical officer on its “Patient Safety Experts to Know " list and the publication CIO placed its CEO among its “The 10 Most Innovative CEOs Making a Difference in 2025.”
The firm has professional affiliations with the Texas Hospital Association, the Georgia Hospital Association, the Hospital Association of Southern California, the Hospital Association of San Diego and Imperial Counties, and the Hospital Council for Northern and Central California. More information on the company and the Glucommander can be found at www.linkedin.com/company/glytec-llc/.